Evidence map›Paper›PMID 42830320›Full record

ArticleEuropean journal of pediatrics2026

Respiratory morbidity at age 4 across COVID-19 and pre-pandemic birth cohorts: the role of atopic risk.

Alma Kamar, Avigdor Mandelberg, NatalyRosenfeld, Diana Tasher, Marina Michleson, Adi Meridor Eisner, Adi Ovadia, Yaara Shen Cohen, Amit Manor, Keren Armoni Domany

Abstract read
In one paragraph

Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alma KamarPediatric Department, Wolfson Medical Center, Holon, Israel.
Avigdor MandelbergPediatric Pulmonology Unit, Wolfson Medical Center, 5822012, Holon, Israel.
NatalyRosenfeldPediatric Department, Wolfson Medical Center, Holon, Israel.
Diana TasherPediatric Department, Wolfson Medical Center, Holon, Israel.
Marina MichlesonPediatric Department, Wolfson Medical Center, Holon, Israel.
Adi Meridor EisnerPediatric Pulmonology Unit, Wolfson Medical Center, 5822012, Holon, Israel.
Adi OvadiaPediatric Department, Wolfson Medical Center, Holon, Israel.
Yaara Shen CohenPediatric Pulmonology Unit, Wolfson Medical Center, 5822012, Holon, Israel.
Amit ManorPediatric Department, Wolfson Medical Center, Holon, Israel.
Keren Armoni DomanyPediatric Pulmonology Unit, Wolfson Medical Center, 5822012, Holon, Israel. kerenar@wmc.gov.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic dramatically reduced early-life respiratory viral exposures, yet the long-term respiratory consequences for pandemic-born children remain unclear. We aimed to compare respiratory morbidity at age 4 between children born during versus before the pandemic and assess whether atopic risk modifies this association. This single-center birth cohort follow-up study included children born in February-March 2020 (COVID-19 cohort) and pre-pandemic controls born during the same period in 2019. Respiratory outcomes at age 4 were assessed using a structured telephone questionnaire (The International Study of Wheezing in Infants). The primary outcome was composite respiratory morbidity (CRM), defined as use of a short-acting bronchodilator (SABA), inhaled and/or oral corticosteroids, and/or emergency room visits for respiratory symptoms. Of 588 eligible children, 329 (55.9%) completed follow-up (139 COVID-19, 190 controls); baseline characteristics, including atopy prevalence, were comparable between cohorts. CRM during the fourth year of life was significantly more common in the COVID-19 cohort (39.6% vs. 27.4%, p = 0.02). In stratified analyses, CRM was markedly higher among atopic-risk pandemic-born children (atopic subgroup: n = 47 COVID-19, n = 68 controls) (66% vs. 27.9%, p < 0.001), but not among non-atopic children (26.1% vs. 27%). Multivariable logistic regression confirmed a significant COVID-19 cohort × atopy interaction for CRM (OR 5.04, 95% CI 1.83-13.89, p = 0.002), while neither factor alone was independently associated with the outcome.

conclusionsBirth during the COVID-19 pandemic was associated with increased preschool respiratory morbidity, particularly among children with atopic risk. These findings suggest that altered early-life microbial exposures may modify respiratory morbidity trajectories according to host atopic susceptibility. WHAT IS KNOWN: • Children born during the COVID-19 pandemic had fewer respiratory infections and wheezing episodes in infancy due to reduced viral circulation. • Atopic predisposition is among the strongest risk factors for recurrent wheezing and persistent asthma in preschool children. WHAT IS NEW: • Pandemic-born children show significantly higher composite respiratory morbidity at age 4, but exclusively among those with atopic risk (OR 5.04). • Neither pandemic birth nor atopy alone predicts excess morbidity-only their combination does, suggesting host susceptibility shapes long-term respiratory trajectories.

Indexed as

COVID-19Hypersensitivity, ImmediateRespiratory Tract DiseasesBirth CohortChild, PreschoolFemaleFollow-Up StudiesHumansMaleRespiratory SoundsRisk FactorsSARS-CoV-2AsthmaAtopyBirth cohortCOVID-19 pandemicWheezing

Identifiers

PMID42830320
PMCPMC13635026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.